These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 32527872)

  • 1. Feasibility study of in vitro drug sensitivity assay of advanced non-small cell lung adenocarcinomas.
    Papp E; Steib A; Abdelwahab EM; Meggyes-Rapp J; Jakab L; Smuk G; Schlegl E; Moldvay J; Sárosi V; Pongracz JE
    BMJ Open Respir Res; 2020 Jun; 7(1):. PubMed ID: 32527872
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human lung adenocarcinoma cell cultures derived from malignant pleural effusions as model system to predict patients chemosensitivity.
    Roscilli G; De Vitis C; Ferrara FF; Noto A; Cherubini E; Ricci A; Mariotta S; Giarnieri E; Giovagnoli MR; Torrisi MR; Bergantino F; Costantini S; Fenizia F; Lambiase M; Aurisicchio L; Normanno N; Ciliberto G; Mancini R
    J Transl Med; 2016 Feb; 14():61. PubMed ID: 26928703
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Clinical Assessment of Chemosensitivity Test in Xeno-free Culture of Autologous 
Malignant Effusion Cells from Patients with Advanced Lung Adenocarcinoma].
    Chen L; Yang S; Jiang J; Zhang Y; Feng H; Cao J; Ge X; Xie W
    Zhongguo Fei Ai Za Zhi; 2016 Sep; 19(9):584-9. PubMed ID: 27666547
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Up-regulated HMGB1 in the pleural effusion of non-small cell lung cancer (NSCLC) patients reduces the chemosensitivity of NSCLC cells.
    Ma Y; Kang S; Wu X; Han B; Jin Z; Guo Z
    Tumori; 2018 Oct; 104(5):338-343. PubMed ID: 28885675
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Feasibility Technique of Low-passage
    Vinayanuwattikun C; Prakhongcheep O; Tungsukruthai S; Petsri K; Thirasastr P; Leelayuwatanakul N; Chanvorachote P
    Anticancer Res; 2019 Dec; 39(12):6981-6988. PubMed ID: 31810970
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Malignant pleural effusion from lung adenocarcinoma treated by gefitinib.
    Kubo A; Koh Y; Kawaguchi T; Isa S; Okamoto I; Fukuoka J; Kusunoki Y; Kitaichi M; Takada M; Nakagawa K
    Intern Med; 2011; 50(7):745-8. PubMed ID: 21467709
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increase of ascites and pleural effusion misleading assessment of antitumor response to erlotinib in adenocarcinoma of the lung.
    Tachihara M; Misa K; Uematsu M; Minemura H; Katsuura Y; Ishida T; Munakata M
    J Clin Oncol; 2011 Aug; 29(23):e675-7. PubMed ID: 21690480
    [No Abstract]   [Full Text] [Related]  

  • 8. Prediction of chemotherapeutic response in unresectable non-small-cell lung cancer (NSCLC) patients by 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2- (4-sulfophenyl)-2H-tetrazolium (MTS) assay.
    Chen J; Cheng GH; Chen LP; Pang TY; Wang XL
    Asian Pac J Cancer Prev; 2013; 14(5):3057-62. PubMed ID: 23803079
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization and drug sensitivity profiling of primary malignant mesothelioma cells from pleural effusions.
    Szulkin A; Otvös R; Hillerdal CO; Celep A; Yousef-Fadhel E; Skribek H; Hjerpe A; Székely L; Dobra K
    BMC Cancer; 2014 Sep; 14():709. PubMed ID: 25253633
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bevacizumab plus chemotherapy in nonsquamous non-small cell lung cancer patients with malignant pleural effusion uncontrolled by tube drainage or pleurodesis: A phase II study North East Japan Study group trial NEJ013B.
    Noro R; Kobayashi K; Usuki J; Yomota M; Nishitsuji M; Shimokawa T; Ando M; Hino M; Hagiwara K; Miyanaga A; Seike M; Kubota K; Gemma A;
    Thorac Cancer; 2020 Jul; 11(7):1876-1884. PubMed ID: 32421226
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcomes of bevacizumab combined with chemotherapy in lung adenocarcinoma-induced malignant pleural effusion.
    Tao H; Meng Q; Li M; Shi L; Tang J; Liu Z
    Thorac Cancer; 2018 Feb; 9(2):298-304. PubMed ID: 29297985
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination chemotherapy in patients with malignant pleural effusions from non-small cell lung cancer : cisplatin, ifosfamide, and irinotecan with recombinant human granulocyte colony-stimulating factor support.
    Fujita A; Takabatake H; Tagaki S; Sekine K
    Chest; 2001 Feb; 119(2):340-3. PubMed ID: 11171707
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Culture and Drug Profiling of Patient Derived Malignant Pleural Effusions for Personalized Cancer Medicine.
    Ruiz C; Kustermann S; Pietilae E; Vlajnic T; Baschiera B; Arabi L; Lorber T; Oeggerli M; Savic S; Obermann E; Singer T; Rothschild SI; Zippelius A; Roth AB; Bubendorf L
    PLoS One; 2016; 11(8):e0160807. PubMed ID: 27548442
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnostic yield of pleural fluid cytology in malignant effusions: an Australian tertiary centre experience.
    Loveland P; Christie M; Hammerschlag G; Irving L; Steinfort D
    Intern Med J; 2018 Nov; 48(11):1318-1324. PubMed ID: 29869427
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intrapleural or intraperitoneal lobaplatin for treatment of patients with malignant pleural effusion or ascites.
    Huang XE; Wei GL; Huo JG; Wang XN; Lu YY; Wu XY; Liu J; Xiang J; Feng JF
    Asian Pac J Cancer Prev; 2013; 14(4):2611-4. PubMed ID: 23725184
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemosensitivity testing of small cell lung cancer using the MTT assay.
    Campling BG; Pym J; Baker HM; Cole SP; Lam YM
    Br J Cancer; 1991 Jan; 63(1):75-83. PubMed ID: 1846554
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase I feasibility and pharmacokinetic study of intrapleural paclitaxel in patients with malignant pleural effusions.
    Perng RP; Wu MF; Lin SY; Chen YM; Lin JY; Whang-Peng J
    Anticancer Drugs; 1997 Jul; 8(6):565-73. PubMed ID: 9300570
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel insights into the systemic treatment of lung cancer malignant pleural effusion.
    Tissot C; Gay P; Brun C; Froudarakis ME
    Clin Respir J; 2019 Mar; 13(3):131-138. PubMed ID: 30737898
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Chemosensitivity test for unresectable non-small cell lung cancer].
    Kawamura M; Inoue Y; Oyama T; Kobayashi K
    Nihon Geka Gakkai Zasshi; 2002 Feb; 103(2):229-32. PubMed ID: 11904985
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vandetanib and indwelling pleural catheter for non-small-cell lung cancer with recurrent malignant pleural effusion.
    Massarelli E; Onn A; Marom EM; Alden CM; Liu DD; Tran HT; Mino B; Wistuba II; Faiz SA; Bashoura L; Eapen GA; Morice RC; Jack Lee J; Hong WK; Herbst RS; Jimenez CA
    Clin Lung Cancer; 2014 Sep; 15(5):379-86. PubMed ID: 24913066
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.